This post was originally published on this site People with rare diseases know that the right government policies can make a big difference in the quality of their own lives, and those of their caregivers. But most lawmakers aren’t experts in even one well-known disease — let alone the world’s estimated 7,000 rare disorders. So…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Amgen and Allergan’s Kanjinti (trastuzumab-anns), a biosimilar to Genentech’s Herceptin (trastuzumab), for all indications of its reference product — including as a treatment for HER2-positive breast cancer, the companies announced. A biosimilar is a biological medical product that is nearly identical…
This post was originally published on this site The first patient has been dosed with Hemispherx Biopharma‘s experimental treatment Ampligen (rintatolimod), in combination with Keytruda (pembrolizumab) and cisplatin, for recurrent ovarian cancer. The investigator-sponsored Phase 2 trial (NCT03734692) is expected to treat 45 ovarian cancer patients who responded to platinum-based chemotherapy for at least six months.…
This post was originally published on this site Interim data from an ongoing Phase 1/2 clinical trial show that Celgene’s investigational therapy iberdomide (CC-220), used in combination with dexamethasone, is safe and controlled disease in nearly 90% of multiple myeloma patients who had failed multiple prior treatments. The preliminary findings were discussed in an oral…
This post was originally published on this site MEI Pharma‘s experimental compound ME-401 reduced tumor burden in 80% of patients with relapsed or refractory follicular lymphoma in a Phase 1 trial, the company said. Responses were comparable among those receiving the treatment alone or in combination with Rituxan (rituximab). Further, the data suggest that the…
This post was originally published on this site About a year ago, I wrote about the blackberry patch in my yard. It’s a wild patch, probably started by a squirrel dropping a berry, and it’s full of thorns. But every spring, I see a daffodil pop up through those thorns. Daffodils are a symbol of…
This post was originally published on this site Adding Tecentriq (atezolizumab) to a combination of Avastin (bevacizumab) and chemotherapy cut the risk of death by nearly half in a group of metastatic non-small cell lung cancer (NSCLC) patients with liver metastasis, an exploratory Phase 3 trial analysis shows. The findings were presented at the 2019…
This post was originally published on this site A new partnership between Susan G. Komen and Cancer Australia will grant a researcher $450,000 over three years to study metastatic breast cancer. Through a Career Catalyst Research Grant provided by the International Collaborative Research Partnership, Delphine Merino of La Trobe University in Australia will focus on providing…
This post was originally published on this site Prostate cancer cells can activate genes associated with bone formation and mimic bone cells’ behavior, allowing them to spread into bones. Those findings by by Duke University researchers, have revealed that targeting this transformation process may represent an alternative strategy to prevent the progression and metastization of…
This post was originally published on this site Maintenance treatment with Rubraca (rucaparib) delays the need for additional treatments among women with platinum-sensitive recurrent ovarian cancer — and then extends the time to disease worsening after those subsequent therapies, a Phase 3 trial found. The exploratory analysis from the ARIEL3 Phase 3 trial (NCT01968213) was…
